AU2018341084B2 - SRPK1 inhibitors - Google Patents
SRPK1 inhibitors Download PDFInfo
- Publication number
- AU2018341084B2 AU2018341084B2 AU2018341084A AU2018341084A AU2018341084B2 AU 2018341084 B2 AU2018341084 B2 AU 2018341084B2 AU 2018341084 A AU2018341084 A AU 2018341084A AU 2018341084 A AU2018341084 A AU 2018341084A AU 2018341084 B2 AU2018341084 B2 AU 2018341084B2
- Authority
- AU
- Australia
- Prior art keywords
- phenyl
- methyl
- compound
- furan
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1715637.3A GB201715637D0 (en) | 2017-09-27 | 2017-09-27 | SRPK1 Inhibitors |
| GB1715637.3 | 2017-09-27 | ||
| GBGB1810765.6A GB201810765D0 (en) | 2018-06-29 | 2018-06-29 | SRPK1 inhibitors |
| GB1810765.6 | 2018-06-29 | ||
| PCT/GB2018/052735 WO2019063996A1 (en) | 2017-09-27 | 2018-09-26 | INHIBITORS OF SRPK1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018341084A1 AU2018341084A1 (en) | 2020-04-23 |
| AU2018341084B2 true AU2018341084B2 (en) | 2023-04-13 |
Family
ID=63722692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018341084A Active AU2018341084B2 (en) | 2017-09-27 | 2018-09-26 | SRPK1 inhibitors |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11420969B2 (enExample) |
| EP (1) | EP3687990A1 (enExample) |
| JP (1) | JP7261793B2 (enExample) |
| CN (1) | CN111448193B (enExample) |
| AU (1) | AU2018341084B2 (enExample) |
| CA (1) | CA3077749A1 (enExample) |
| WO (1) | WO2019063996A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3821947A1 (en) * | 2019-11-13 | 2021-05-19 | Libra Therapeutics, Inc. | Heterocyclic trpml1 agonists |
| GB202010829D0 (en) | 2020-07-14 | 2020-08-26 | Exonate Ltd | Compounds for treatment of neovascular diseases |
| WO2024155864A1 (en) * | 2023-01-20 | 2024-07-25 | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. | Sprk1 inhibitors and methods of use |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014060763A1 (en) * | 2012-10-17 | 2014-04-24 | The University Of Bristol | Compounds useful for treating ocular neovasculan |
| WO2015159103A1 (en) * | 2014-04-17 | 2015-10-22 | The University Of Nottingham | Piperazine derivatives for treating disorders |
| WO2017064512A1 (en) * | 2015-10-16 | 2017-04-20 | Exonate Limited | Compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE462006T1 (de) | 2001-08-01 | 2010-04-15 | Univ Bristol | Isoform des vegfs |
| CA2536964A1 (en) * | 2003-04-25 | 2004-11-11 | Ortho-Mcneil Pharmaceutical, Inc. | C-fms kinase inhibitors |
| AU2004308825B2 (en) | 2003-12-26 | 2011-03-10 | Masatoshi Hagiwara | Method of regulating phosphorylation of SR protein and antiviral agents comprising SR protein activity regulator as the active ingredient |
| US20140249135A1 (en) | 2007-03-01 | 2014-09-04 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| CN101679266B (zh) | 2007-03-01 | 2015-05-06 | 诺华股份有限公司 | Pim激酶抑制剂及其应用方法 |
| GB0704678D0 (en) | 2007-03-09 | 2007-04-18 | Univ Bristol | Pro- and anti-angiogenic treatments |
| JP5349309B2 (ja) * | 2007-08-03 | 2013-11-20 | 株式会社キノファーマ | 抗ｄｎａウイルス作用を有するアニリン誘導体 |
| GB0803912D0 (en) | 2008-02-29 | 2008-05-07 | Univ Bristol | Novel Uses of VEGFxxxb |
| WO2010058227A2 (en) | 2008-11-22 | 2010-05-27 | The University Of Bristol | NOVEL USES OF VEGFxxxB |
| WO2011036429A1 (en) | 2009-09-25 | 2011-03-31 | The University Of Bristol | Detection of risk of pre-eclampsia |
| GB201009173D0 (en) | 2010-05-28 | 2010-07-14 | Univ Bristol | Treatment of pain |
-
2018
- 2018-09-26 CA CA3077749A patent/CA3077749A1/en active Pending
- 2018-09-26 JP JP2020517549A patent/JP7261793B2/ja active Active
- 2018-09-26 US US16/651,182 patent/US11420969B2/en active Active
- 2018-09-26 EP EP18782140.0A patent/EP3687990A1/en active Pending
- 2018-09-26 AU AU2018341084A patent/AU2018341084B2/en active Active
- 2018-09-26 WO PCT/GB2018/052735 patent/WO2019063996A1/en not_active Ceased
- 2018-09-26 CN CN201880075104.5A patent/CN111448193B/zh active Active
-
2022
- 2022-08-04 US US17/880,925 patent/US12325704B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014060763A1 (en) * | 2012-10-17 | 2014-04-24 | The University Of Bristol | Compounds useful for treating ocular neovasculan |
| WO2015159103A1 (en) * | 2014-04-17 | 2015-10-22 | The University Of Nottingham | Piperazine derivatives for treating disorders |
| WO2017064512A1 (en) * | 2015-10-16 | 2017-04-20 | Exonate Limited | Compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020535172A (ja) | 2020-12-03 |
| AU2018341084A1 (en) | 2020-04-23 |
| CN111448193A (zh) | 2020-07-24 |
| US20220389015A1 (en) | 2022-12-08 |
| WO2019063996A1 (en) | 2019-04-04 |
| US12325704B2 (en) | 2025-06-10 |
| CA3077749A1 (en) | 2019-04-04 |
| US11420969B2 (en) | 2022-08-23 |
| JP7261793B2 (ja) | 2023-04-20 |
| CN111448193B (zh) | 2023-12-22 |
| EP3687990A1 (en) | 2020-08-05 |
| US20200270249A1 (en) | 2020-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017331345B2 (en) | Compounds and methods for IDO and TDO modulation, and indications therefor | |
| US12325704B2 (en) | SRPK1 inhibitors | |
| JP6876685B2 (ja) | Ａｔｘ阻害剤としての二環式化合物 | |
| EP3033335B1 (en) | Pyridinones | |
| AU2008258366B2 (en) | 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as Met kinase inhibitors for the treatment of tumors | |
| AU2016337309B2 (en) | Compounds | |
| JP2018524372A (ja) | Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物 | |
| AU2009266756B2 (en) | Triazole derivative or salt thereof | |
| TW201840552A (zh) | 作為atx抑制劑之新穎雙環化合物 | |
| AU2017365123B2 (en) | Heteroarylphenoxy benzamide kappa opioid ligands | |
| AU2013225173A1 (en) | 6 - alkynyl pyridines as SMAC mimetics | |
| CA3108809C (en) | Heteroaromatic compounds, pharmaceutical compositions and uses thereof | |
| AU2010341229A1 (en) | Sphingosine kinase inhibitors | |
| AU2010333338A1 (en) | Sphingosine kinase inhibitors | |
| CA3179059A1 (en) | Collagen 1 translation inhibitors and methods of use thereof | |
| CA3107897A1 (en) | Fused ring derivative used as fgfr4 inhibitor | |
| US20220370431A1 (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
| EP4463452B1 (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
| WO2012152854A1 (en) | Metabotropic glutamate receptor modulators | |
| US20050004200A1 (en) | Pyrazole compounds as integrin receptor antagonists derivatives | |
| EP4584267A1 (en) | Novel compounds as ck2 inhibitors | |
| CA3094714A1 (en) | Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |